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RISK FACTORS FOR STENOTROPHOMONAS MALTOPHILIA
BACTEREMIA IN ONCOLOGY PATIENTS:
A CASE–CONTROL STUDY
Anucha Apisarnthanarak, MD; Jennie L. Mayfield, BSN, MPH; Teresa Garison, BSN, MSN; Patricia M. McLendon, MPH; 
John F. DiPersio, MD, PhD; Victoria J. Fraser, MD; Louis B. Polish, MD
Stenotrophomonas maltophilia, formerly known as
Pseudomonas maltophilia, is a nonfermentative, gram-nega-
tive bacillus that has been isolated from human feces, ani-
mals, intravenous solution, and environmental sources
including water, soil, sewage, and raw milk.1-4 Although it is
usually considered a colonizer and is rarely responsible for
community-acquired infections,5 its role as a pathogen has
been increasingly recognized among immunocompro-
mised patients, especially patients with malignancies.2,6-8
S. maltophilia accounted for 0.6% to 0.9% of all blood-
stream infections reported from the United States, Canada,
and Latin America from 1997 through 1999.9,10 Septicemia
due to this organism occurs rarely, although several noso-
comial outbreaks have been reported.3,8,11-16 Recognized
risk factors associated with Stenotrophomonas bacteremia
include antibiotic pressure, presence of a central venous
catheter, prolonged hospital stay, length of intensive care
unit stay, mechanical ventilation, and aggressive
chemotherapy treatment for malignancies.2,3,6-8,11,13,17-21 In
addition, severe neutropenia (neutrophil count < 50/mm3)
and mucositis were shown to be significant risk factors for
S. maltophilia bacteremia in a recent outbreak study of
patients receiving allogeneic bone marrow transplants.8
From June 1999 through April 2001, 13 patients on
the transplantation unit acquired S. maltophilia bacteremia
compared with 1 patient between July 1997 and May 1999.
During this period, the incidence rate of S. maltophilia bac-
teremia on the oncology service was 94 per 10,000 admis-
sions versus 7 per 10,000 admissions during the prior 23
months (P = .001) (Fig. 1). Incidence rates of other water-
borne, gram-negative bacteremia did not change during
this period. In an effort to characterize risk factors for S.
maltophilia bacteremia among oncology patients, a
case–control study was conducted.
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OBJECTIVE: To characterize risk factors for
Stenotrophomonas maltophilia bloodstream infection in oncology
patients.
DESIGN: A 3:1 case–control study.
SETTING: Stem Cell Transplant and Leukemic Center at
Barnes–Jewish Hospital (St. Louis), a 1,442-bed, tertiary-care
teaching hospital with a 26-bed transplantation ward.
METHOD: From June 1999 to April 2001, 13 patients with
S. maltophilia bacteremia were compared with 39 control-
patients who were on the transplantation unit on the same day as
the case-patients’ positive blood cultures. Information collected
included patient demographics, medical history, history of trans-
plantation, transplantation type, graft versus host disease, neu-
tropenia, antibiotic use, chemotherapy, mucositis, diarrhea, the
presence of central venous catheter(s), cultures, and concomi-
tant infections.
RESULTS: Significant risk factors for S. maltophilia bac-
teremia included severe mucositis (7 [53.8%] of 13 vs 8 [20.5%] of
39; P = .034), diarrhea (7 [53.8%] of 13 vs 8 [20%] of 39; P = .034),
and the use of metronidazole (9 [69.2%] of 13 vs 8 [20.5%] of 39; P
= .002). In addition, the number of antibiotics used (median, 9 vs 5;
P < .001), duration of mucositis (median, 29 vs 15 days; P = .032),
and length of hospital stay (median, 34 vs 22 days; P = .017) were
significantly different between case- and control-patients. Nine S.
maltophilia isolates tested by pulsed-field gel electrophoresis were
found to be distinctly different.
CONCLUSION: Interventions to ameliorate the severity
of mucositis, reduce antibiotic pressure, prevent diarrhea, and pro-
mote meticulous central venous catheter care may help prevent S.
maltophilia bloodstream infection in oncology patients. The role of
gastrointestinal tract colonization as a potential source of S. mal-
tophilia bacteremia in oncology patients deserves further investi-
gation (Infect Control Hosp Epidemiol 2003;24:269-274). 
ABSTRACT
270 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY April 2003
METHODS
Setting
Barnes–Jewish Hospital is a 1,442-bed, tertiary-care
teaching hospital with a 26-bed transplantation ward. In the
year 2000, the Stem Cell Transplant and Leukemic Center
program performed a total of 225 transplants (123 [55%]
autologous and 102 [45%] allogeneic transplants) with a
total of 10,260 patient-days and 600 admissions. The Stem
Cell Transplant and Leukemic Center program also treats
patients with leukemia with aggressive or recurrent dis-
ease that fails to respond to chemotherapy. All patients who
underwent autologous transplants received peripheral
blood stem cell transplants, whereas 45% and 55% of
patients receiving allogeneic transplants underwent bone
marrow and peripheral blood stem cell transplants, respec-
tively.
Case Stratification and Ascertainment
A case-patient was defined as any oncology patient
hospitalized at the Stem Cell Transplant and Leukemic
Center at Barnes–Jewish Hospital from June 1, 1999,
through April 30, 2001, for whom S. maltophilia was isolat-
ed from one or more blood cultures. Patient identification
was based on review of microbiology laboratory data.
Medical records were reviewed to ascertain that these
patients developed S. maltophilia bacteremia and were
associated with clinical infection. Control-patients were ran-
domly selected from patients who did not develop bac-
teremia and were on the same unit on the day of the case-
patient’s first positive blood culture for S. maltophilia.
Room numbers were drawn randomly to select the control-
patients. Centers for Disease Control and Prevention defin-
itions for bloodstream and other nosocomial infections
were applied for all case- and control-patients.22 For organ-
isms likely to be due to skin contamination, such as coagu-
lase-negative Staphylococcus species and Corynebacterium
species, bacteremia was defined by a temperature of 38°C
or greater with two positive blood cultures within 24 hours.
Case–Control Study
To determine risk factors for S. maltophilia bac-
teremia among oncology patients, 13 case-patients were
compared with 39 control-patients (3 control-patients per
case-patient). Information collected on case- and control-
patients included demographics, medical history, history of
transplantation, transplantation type, graft versus host dis-
ease, neutropenia, prophylactic and therapeutic antimicro-
bial use, chemotherapy, the presence of central venous
catheters, mucositis, severe mucositis (defined by ulcers
with plaques involving more than 25% or hemorrhagic
ulcers of the oral mucosa), diarrhea, and other concurrent
infections. Therapeutic antibiotics analyzed included 
penicillin, extended-spectrum penicillins, first-, second-,
third-, and fourth-generation cephalosporins, quinolones,
aminoglycosides, glycopeptides, macrolides, metronida-
zole, clindamycin, cotrimoxazole, chloramphenicol, strep-
togramins, oxazolidinones, and carbapenems. In addition,
prophylactic antibiotic (cotrimoxazole), antiviral (acyclovir,
famcyclovir, and gancyclovir), and antifungal (polyenes and
azoles) medications were included in the analysis. With the
exception of diarrhea, all risk factors were evaluated from
the time of admission until the occurrence of S. maltophil-
ia bacteremia for case-patients and during the entire hospi-
tal stay for control-patients. Diarrhea was defined as 3 or
more loose or watery stools in 24 hours within 72 hours
before the onset of bacteremia for case-patients and any
time during the entire hospital stay for control-patients. 
The population of the Stem Cell Transplant and
Leukemic Center included patients with leukemia who did
not receive transplants and patients who underwent allo-
geneic and autologous transplants. To determine risk fac-
tors for S. maltophilia bacteremia in patients undergoing
transplants, we compared 6 case-patients who had received
their transplants within 6 months prior to the hospitaliza-
tion during which S. maltophilia bacteremia was detected
with 20 patients (control-patients) who received a trans-
plant during the same time period. To further determine
risk factors for S. maltophilia bacteremia in allogeneic
transplantation, we restricted the analysis to 5 case-patients
who had received an allogeneic transplant within 6 months
of the hospitalization during which S. maltophilia bac-
teremia was detected. These 5 case-patients were com-
pared with 11 patients receiving allogeneic transplants
(control-patients) who were hospitalized during the same
time period. These patients were compared regarding all of
the characteristics described above.
Nursing Care, Infection Control Practices, and
Supportive Anti-Infectious Therapy
During the study period, there was no change in
standard nursing care practices (eg, mucosal care for
patients with severe mucositis). Standard precautions were
applied to all patients. Contact precautions were used when
patients were identified as having multidrug-resistant
organisms or epidemiologically significant organisms such
as S. maltophilia. For Pneumocystis carinii pneumonia pro-
phylaxis, patients received oral cotrimoxazole, starting on
the day of engraftment. To prevent endogenous reactiva-
tion of herpes simplex virus and human cytomegalovirus,
patients received prophylactic intravenous or oral treat-
FIGURE 1. Distribution of cases in which Stenotrophomonas maltophilia was
isolated in recent years in the Stem Cell Transplant and Leukemic Center.
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ment with acyclovir at a dosage of 30 mg/kg starting 2 days
before to 30 days after transplantation. Recombinant
human granulocyte colony-stimulating factor was given to
all patients after transplantation to accelerate the kinetics of
neutrophil recovery. In our Stem Cell Transplant and
Leukemic Center, a fourth-generation cephalosporin was
used for empirical treatment of febrile neutropenia, and
antifungal therapy (azoles and polyenes) was employed in
the presence of clinical evidence of fungal infection or fever
persisting after 5 days of antibiotic therapy. In addition,
metronidazole was started empirically for most patients
who developed diarrhea. 
Microbiological Characterization
All clinical isolates were identified to the species
level using VITEK-GNI Cards (bioMérieux VITEK,
Hazelwood, MO). If the probability of S. maltophilia was
less than 85% by VITEK-GNI Cards, the organism was con-
firmed by the API 20 NE system (bioMérieux VITEK). S.
maltophilia recovered from case-patients were genotyped
by pulsed-field gel electrophoresis with the use of DNA
digested with SpeI and XbaI and separated by means of a
CHEF Mapper XA apparatus (Biorad, Hercules, CA).
Because all organisms tested by pulsed-field gel elec-
trophoresis were found to be distinctly different and all
case-patients were admitted to different rooms, no environ-
mental samples were taken.
Statistical Methods
Data were collected by an infectious disease fellow
and an infection control specialist. SPSS software (version
10.0; SPSS, Inc., Chicago, IL) was used to analyze the data.
Proportions were compared using the chi-square or
Fisher’s exact test, as appropriate. Continuous variables
were compared using the Mann–Whitney test. All P values
were two-tailed; a P value of .05 or less was considered sta-
tistically significant.
RESULTS
Descriptive Epidemiology
From June 1, 1999, to April 30, 2001, 13 hematol-
ogy–oncology patients with S. maltophilia bacteremia met
the case-patient definition. During this period, the inci-
dence of S. maltophilia bacteremia on the transplantation
unit was 94 per 10,000 admissions or 76 per 1,000 hospital-
days compared with 7 per 10,000 admissions or 6 per 1,000
hospital-days during the previous 23 months (P = .001)
(Fig. 1). Diarrhea developed in 8 case-patients within 72
hours prior to the development of bacteremia (5 [71%] in
primary bloodstream infection, 2 [29%] in secondary blood-
stream infection). The demographic and medical charac-
teristics of case-patients and control-patients are detailed in
Table 1. For case-patients, the median duration from cen-
tral venous catheter insertion to the development of bac-
teremia was 60 days (range, 11 to 325 days). The median
TABLE 1
CHARACTERISTICS OF CASES VERSUS CONTROLS IN HOSPITALIZED
HEMATOLOGY–ONCOLOGY PATIENTS
Cases Controls
(N = 13) (N = 39)
Characteristic No. (%) No. (%) P
Gender
Male 10 (77) 25 (64) .50
Female 3 (23) 14 (36) .73
Diabetes mellitus 2 (15) 6 (15) 1.00
Hematologic 
malignancy
Acute leukemia 9 (69) 21 (54) .51
Lymphoma 1 (7.7) 11 (28) .25
Other 1 (7.7) 12 (31) .14
Solid tumors 4 (30.7) 4 (10.2) .09
Bone marrow 
transplantation
Allogeneic 5 (38) 11 (28) .50
Autologous 1 (7.7) 9 (23) .42
Chemotherapy 10 (77) 30 (77) 1.00
Antibacterial 
prophylaxis
Quinolone 3 (23) 5 (13) .66
Trimethoprim–
sulfamethoxazole 1 (7.7) 5 (13) 1.00
Therapeutic anti-
microbials
Extended-spectrum 
penicillin 4 (30.7) 4 (10.2) .09
Fourth-generation 
cephalosporin 11 (85) 26 (67) .30
Imipenem 7 (53.8) 11 (28) .10
Central venous 8 (61.5) 24 (61.5) 1.00
catheter
Neutropenia 11 (85) 29 (74.3) .70
Mortality 4 (30.7) 5 (13) .20
TABLE 2
UNIVARIATE ANALYSIS OF RISK FACTORS FOR STENOTROPHOMONAS
MALTOPHILIA BLOODSTREAM INFECTION IN HOSPITALIZED
HEMATOLOGY–ONCOLOGY PATIENTS
Dichotomous
Variable OR CI95 P*
Severe mucositis 4.52 1.18 to 17.2 .03
Diarrhea† 4.52 1.18 to 17.2 .03
Metronidazole use 8.71 2.16 to 35.75 .002
Graft versus host disease 1 0.09 to 10.54 1.00
Mucositis 0.64 0.05 to 7.80 1.00
Neutropenia 1.89 0.35 to 10.06 .70
OR = odds ratio; CI95 = 95% confidence interval.
*Analyzed by chi-square test.
†Diarrhea within 72 hours prior to bacteremia.
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duration from admission to the development of mucositis
was 2 days (range, 0 to 31 days) and the median duration
from admission to the development of S. maltophilia bac-
teremia was 14 days (range, 1 to 50 days). Nine patients
died (4 of 13 case-patients vs 5 of 39 control-patients). The
crude mortality rate was 30.7% for case-patients and 12.8%
for control-patients (P = .20; 95% confidence interval [CI95],
0.52 to 17.31).
Univariate Analysis (Tables 2 and 3)
There were no statistically significant differences
between case- and control-patients regarding demographic
characteristics and underlying diseases (Table 1). When
compared with control-patients concurrently hospitalized
on the transplantation unit, case-patients were significantly
more likely to have severe mucositis (7 [53.8%] of 13 vs 8
[20.5%] of 39; odds ratio [OR], 4.52; P = .034; CI95, 1.18 to
17.24), to have diarrhea (7 [53.8%] of 13 vs 8 [20%] of 39;
OR, 4.52; P = .034; CI95, 1.18 to 17.24), and to have been
given metronidazole (9 [69.2%] of 13 vs 8 [20.5%] of 39; OR,
8.719; P = .002; CI95, 2.16 to 35.75). We evaluated the corre-
lation between diarrhea and S. maltophilia bacteremia in
subgroups of case-patients (primary vs secondary blood-
stream infection). Between these two subgroups, a signifi-
cant correlation between diarrhea and S. maltophilia was
observed only in patients with primary bloodstream infec-
tion (5 [71.4%] of 7 vs 8 [20.5%] of 39; OR, 9.68; P = .014;
CI95, 1.57 to 59.47).
We evaluated metronidazole use with neutropenia,
mucositis, severe mucositis, diarrhea, Clostridium diffi-
cile–associated diarrhea, and vancomycin-resistant
Enterococcus (VRE) colonization. Of all risk factors evaluat-
ed, the use of metronidazole was significantly associated
with diarrhea (diarrhea with metronidazole use vs diarrhea
without metronidazole use: 10 [58.8%] of 17 vs 4 [11.4%] of
35; OR, 11.07; P = .001; CI95, 2.67 to 45.81) and Clostridium
difficile–associated diarrhea (with metronidazole use vs
without metronidazole use: 6 [35.2%] of 17 vs 2 [5.7%] of 35;
OR, 9.00; P = .011; CI95, 1.58 to 51.26). There were no dif-
ferences among case- and control-patients regarding other
anti-anaerobic medications (clindamycin, extended-spec-
trum penicillin, and imipenem).
Case-patients were also more likely to have a pro-
longed hospital stay (median, 34 vs 22 days; P = .017) and
duration of mucositis (median, 29 vs 15 days; P = .032), and
to have been treated with a greater number of antibiotics
(median, 9 vs 5; P < .001) (Mann–Whitney test). There
were no significant differences between case- and control-
patients regarding the other characteristics and risk factors
examined, including previous (from 6 months prior) and
recent history and type of transplantation, chemotherapeu-
tic regimen, graft versus host disease, neutropenia, human
leukocyte antigen matching, receipt of prophylactic or ther-
apeutic antimicrobials, catheter insertion, duration of
catheter insertion, and mucositis. There were no signifi-
cant differences between case- and control-patients in
subgroups of patients who underwent transplantation (allo-
geneic and autologous) regarding demographic character-
istics and risk factors examined. The actual cause of the
increase in S. maltophilia bacteremia was not discovered.
Microbiology
For all case-patients, S. maltophilia was initially iso-
lated from blood cultures (range, one to five sets of positive
blood cultures per case-patient) and was associated with
clinical infection. Six (46%) of 13 case-patients had S. mal-
tophilia presenting as secondary infection (3 [23%] respira-
tory tract and 3 [23%] wound). Seven case-patients (54%)
developed primary S. maltophilia bacteremia after receiv-
ing cytotoxic chemotherapy and were neutropenic on the
day of the positive culture. The patient who had only one
positive blood culture developed S. maltophilia bacteremia
secondary to S. maltophilia pneumonia.
Polymicrobial bacteremia was identified in 3 of 13
case-patients. The source of S. maltophilia bacteremia in
these patients was pneumonia (1 patient; 33.3%), wound (1
patient; 33.3%), or primary bloodstream infection (1 patient;
33.3%). Most of these organisms were enteric microorgan-
isms. Organisms isolated from case-patients with polymi-
crobial bacteremias were Escherichia coli (1), Klebsiella
pneumoniae (1), Lactobacillus species (1), Alcaligenes
xylosoxidans (1), Enterococcus faecalis (1), and coagulase-
negative Staphylococcus species (1).
All patients were treated with intravenous antibiotics;
TABLE 3
UNIVARIATE ANALYSIS OF RISK FACTORS FOR STENOTROPHOMONAS MALTOPHILIA BLOODSTREAM INFECTION IN HOSPITALIZED
HEMATOLOGY–ONCOLOGY PATIENTS
Median
Continuous Variable Case-Patient (Interquartile Range) Control-Patient (Interquartile Range) P*
Length of hospital stay, d 34 (19.0 to 55.5) 22 (14.5 to 34.7) .01
Duration of mucositis, d 29 (15.7 to 49.7) 15 (10.5 to 21.0) .03
No. of antibiotics used 9 (6.0 to 10.5) 5 (4.0 to 7.0) < .001
Duration of neutropenia, d 20 (8.0 to 36.0) 12 (7.0 to 15.5) .09
Duration of antibiotics, d 17 (13.5 to 38.5) 22 (13.0 to 32.0) .97
*Analyzed by Mann–Whitney test.
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5 (71%) of 7 case-patients with primary bloodstream infec-
tion also had their catheters removed at the discretion of
attending physicians to prevent possible complications.
There was no recurrent infection in any of the 7 patients.
Pulsed-field gel electrophoresis was performed on 9 case
isolates from blood and all were distinctly different (Fig. 2).
No case-patients had been admitted to a room that had
been occupied by another case-patient, and as a result, no
environmental cultures were performed.
DISCUSSION
In our investigation, severe mucositis, diarrhea, and
the use of metronidazole were significant risk factors for S.
maltophilia bacteremia. Subgroup analysis of case-patients
revealed a significant correlation between diarrhea and S.
maltophilia bacteremia only in patients with primary blood-
stream infection (5 [71.4%] of 7 vs 8 [20.5%] of 39; P = .014).
In addition, case-patients were more likely to have pro-
longed duration of mucositis and hospitalization, and to
have received more antibiotics. Recognized risk factors for
S. maltophilia bacteremia in oncology patients have includ-
ed severe and prolonged neutropenia, intravascular
devices, prolonged hospital stay, aggressive chemotherapy
treatment, and increased antibiotic pressure.2,6-8,23,24 Severe
mucositis was recently identified as a significant risk factor
for S. maltophilia bacteremia in the investigation of an out-
break among patients receiving bone marrow transplants.8
Our study confirmed the association of severe mucositis
with S. maltophilia bacteremia in oncology patients.
Because all risk factors were evaluated from the time of
admission until the occurrence of S. maltophilia bac-
teremia for case-patients and during the entire hospital stay
for control-patients, any potential bias that occurred would
strengthen our findings.
Sources of S. maltophilia bacteremia have included
central venous or arterial catheters, wounds, skin and soft
tissue, and respiratory, urinary, and gastrointestinal
tracts.1,6 Central venous catheters are the most frequently
implicated as the source of S. maltophilia bloodstream
infection.19 It has also been suggested that S. maltophilia
can be found colonizing the gastrointestinal tract in oncol-
ogy patients.23 In our study, the significance of severe
mucositis, prolonged duration of mucositis, and diarrhea
(within a 72-hour period prior to bacteremia) suggested
that severe and prolonged gastrointestinal mucosal break-
down may aid in the development of S. maltophilia bac-
teremia in oncology patients, if they are previously colo-
nized.8,23
The use of metronidazole and the increased number
of antibiotics used were significant factors associated with
Stenotrophomonas bloodstream infection in our investiga-
tion. Although not statistically significant, case-patients
were more likely to have received imipenem (7 [53.8%] of
13 vs 11 [28.2%] of 39; P = .10) and extended-spectrum peni-
cillins (4 [31%] of 13 vs 4 [10.3%] of 39; P = .09). The antibi-
otic preferences of different faculty and prolonged length
of hospital stay in case-patients increase the possibility of
receiving more antibiotics. Because metronidazole was
used empirically for most patients who developed diarrhea,
the correlation between metronidazole use and Clostridium
difficile–associated diarrhea or other diarrhea was not sur-
prising.
Outbreaks of S. maltophilia have been identified with
nosocomial cross-transmission from patient to patient and
from the hospital environment and equipment, including
aerosol nebulizers, tracheal suction catheters, faucet aera-
tors, and respirator circuits.6,15,21,25-27 In our study, the het-
erogeneity of the S. maltophilia strain types documented
by pulsed-field gel electrophoresis of nine isolates suggest-
ed that the organisms came from multiple sources.
Our study has several limitations. S. maltophilia is
not a common occurrence and the small sample size of our
study limits our capability of performing multivariate analy-
sis. In addition, the large confidence intervals of the odds
ratios prevent true quantification of the degree of risk
posed by diarrhea in subgroups of patients who developed
primary bloodstream infection. The lack of prospective
stool cultures and pulsed-field gel electrophoresis to assess
the source of Stenotrophomonas bacteremia in primary
infection make it difficult to ascertain the true relationship
FIGURE 2. Pulsed-field gel electrophoresis banding patterns of DNA seg-
ments (digested with SpeI) from Stenotrophomonas maltophilia isolates that
were recovered from our hematology–oncology patients on the stem cell
transplant unit at Barnes–Jewish Hospital (St. Louis). All nine case isolates
were distinctly different. Lane 1 = molecular standard; lane 2 = S. mal-
tophilia quality control strain; and lanes 3 to 11 = the S. maltophilia isolate
from patients 1 to 9.
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between gastrointestinal colonization and the development
of S. maltophilia bacteremia. Although diarrhea, severe
mucositis, and metronidazole use were associated with S.
maltophilia bacteremia in our study, we were not able to
identify the actual cause of the S. maltophilia bacteremia.
Our investigation confirmed the relevance of severe
mucositis, antibiotic pressure, and prolonged hospital stay
as risk factors for S. maltophilia bacteremia. Given the sig-
nificance of diarrhea in our study, gastrointestinal tract col-
onization should be evaluated as a potential source of S.
maltophilia bacteremia. Interventions to ameliorate the
severity of mucositis and attempts to decrease antibiotic
pressure, prevent diarrhea, and promote meticulous cen-
tral venous catheter care may help prevent Steno-
trophomonas bloodstream infection in oncology patients.
Further studies to determine the prevalence of gastroin-
testinal carriage, environmental reservoirs, and the corre-
lation between gastrointestinal carriage and Steno-
trophomonas bloodstream infection are warranted to help
devise infection control strategies for high-risk patients.
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